Get notified when PFSA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsProfusa eliminates 12% management equity grant tied to $30M asset acquisition
Filed May 26, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Company removed provision granting CEO and CFO 12% of fully diluted shares upon closing its $30M PanOmics Assay acquisition, eliminating significant shareholder dilution originally structured as management retention incentive.
Item 1.01 verify on EDGAR → -
high
Amendment modifies April 2026 agreement to acquire PanOmics Assay technology from Bio Insights LLC for $30M in newly created Series A Convertible Preferred Stock, with no cash consideration.
Item 1.01 verify on EDGAR → -
medium
PanOmics Assay is an integrated NGS multi-omics analysis platform combining genomics, transcriptomics, and metabolomics used in drug discovery and precision medicine.
Item 1.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade PFSA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · May 27, 2026 9:06 PM